PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On December15, 2016, the Board of Directors of Puma
Biotechnology, Inc. (the Company) authorized the Company to
transfer the listing of its common stock, par value $0.0001 per
share (Common Stock), from The New York Stock Exchange (the NYSE)
to The NASDAQ Stock Market (NASDAQ). On December19, 2016, the
Company provided written notice to the NYSE of its intention to
voluntarily delist its Common Stock from the NYSE and to list its
Common Stock on NASDAQ. The Company expects the listing and
trading of its Common Stock on the NYSE to cease at the close of
trading on December30, 2016 and that trading of its Common stock
will commence on NASDAQ on the next business day, January3, 2017.
The Companys Common Stock has been approved for listing on NASDAQ
and will continue to trade under the stock symbol PBYI.
A copy of the press release issued by the Company in connection
with the transfer of the listing of its Common Stock from the
NYSE to NASDAQ is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press Release dated December19, 2016 |
About PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Recent Trading Information
PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) closed its last trading session down -1.20 at 35.05 with 539,945 shares trading hands.